A comprehensive system to explore p53 mutations

American Journal of Clinical Pathology

Volumn 110, Issue 3, 1998, Pages 368-373

  Furuwatari, Chizumi ^a   Yagi, Asako ^a   Yamagami, Osamu ^a   Ishikawa, Masayo ^a   Hidaka, Eiko ^a   Ueno, Ichiro ^a   Furihata, Kenichi ^b   Ogiso, Yoshifumi ^a   Katsuyama, Tsutomu ^b  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

FISH; Fluorescence in situ hybridization; Immunohistochemistry; p53 mutations; PCR SSCP; Polymerase chain reaction single strand conformation polymorphism

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOME; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0031755161     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/110.3.368     Document Type: Article

References (10)

1. Mendelsohn J, Howley PM, Israel MA, et al. The Molecular Basis of Cancer. Philadelphia, Pa: Saunders; 1995:94-98.
2. Malkin D, Li FP, Strong LC, et al. Germline mutation in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238.
3. Mashiyama S, Murakami Y, Yoshimoto T, et al. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism of polymerase chain reaction products. Oncogens. 1995;6:1313-1318.
4. Dohner H, Fisher K, Beutz M, et al. p53 gene deletion predicts for poor survival and no response to therapy with purine analog in chronic B-cell leukemias. Blood. 1995;85: 1580-1589.
5. Baas IO, Mulder JR, Offerhaus GJA, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994; 172:5-12.
6. Gomyo Y, Osaki M, Kaibara N, et al. Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer. 1996;66:594-599.
7. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc700-p53 complex with an altered half-life. Mol Cell Biol. 1988;8:531-539.
8. Mohabeer AJ, Hiti AL, Martin WJ. Non-radioactive single strand conformation polymorphism (SSCP) using the Pharmacia 'PhastSystem'. Nucleic Acids Res. 1991;19:3154.
9. Redston MS, Caldas C, Seyymour AB, et al. P53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54:3025-3033.
10. Nguyen DM, Spitz FR, Yen N, et al. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systematic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg. 1996;112: 1372-1376.